Basking Biosciences is developing the first reversible thrombolytic therapy for Acute Ischemic Stroke (AIS), focusing on RNA aptamers to target von Willebrand Factor (vWF) for safer and more effective treatment of acute thrombotic conditions
Basking Biosciences is developing the first reversible thrombolytic therapy for Acute Ischemic Stroke (AIS), focusing on RNA aptamers to target von Willebrand Factor (vWF) for safer and more effective treatment of acute thrombotic conditions.